Department of Anesthesiology, Chi Mei Medical Center, Tainan City, 71004, Taiwan.
Department of Hospital and Health Care Administration, College of Recreation and Health Management, Chia Nan University of Pharmacy and Science, Tainan City , 71710, Taiwan.
Obes Surg. 2022 Aug;32(8):2734-2743. doi: 10.1007/s11695-022-06109-6. Epub 2022 May 17.
This meta-analysis investigated the effect of oral gabapentinoids (i.e., pregabalin and gabapentin) on analgesic consumption (i.e., primary outcome) and pain relief (i.e., secondary outcome) in patients following bariatric surgery. Analysis of five eligible trials published between 2010 and 2019 including 363 participants receiving gabapentinoids revealed a significantly lower morphine consumption [mean difference (MD) = - 15.1 mg, p = 0.004; evidence certainty: low] and risk of nausea/vomiting [risk ratio (RR) = 0.49, p = 0.002; evidence certainty: high] at postoperative 6-24 h. There was also a lower pain score at postoperative 0-4 h (MD = - 1.41, p < 0.00001; evidence certainty: low) and 6-12 h (MD = - 0.9, p = 0.007; evidence certainty: low) compared with controls, while pain severity at postoperative 24 h was comparable between two groups. In summary, preoperative oral gabapentinoids optimized postoperative pain outcomes and reduced risk of nausea/vomiting following bariatric surgery.
本荟萃分析研究了口服加巴喷丁类药物（即普瑞巴林和加巴喷丁）对减重手术后患者的镇痛药物消耗（即主要结局）和疼痛缓解（即次要结局）的影响。分析了 2010 年至 2019 年期间发表的五项符合条件的试验，共纳入 363 名接受加巴喷丁类药物治疗的患者，结果显示，术后 6-24 小时，加巴喷丁类药物组吗啡消耗量显著降低[均数差值（MD）=-15.1mg，p=0.004；证据确定性：低]，恶心/呕吐的风险降低[风险比（RR）=0.49，p=0.002；证据确定性：高]。术后 0-4 小时（MD=-1.41，p<0.00001；证据确定性：低）和 6-12 小时（MD=-0.9，p=0.007；证据确定性：低），加巴喷丁类药物组的疼痛评分也较低，而两组患者在术后 24 小时的疼痛严重程度无显著差异。总之，术前口服加巴喷丁类药物可优化减重手术后的疼痛结局，并降低恶心/呕吐的风险。
